3 Excellent Dividend Stocks to Buy on the Dip

The article highlights AbbVie, Walmart, and Becton Dickinson as long-term dividend stocks, emphasizing 50+ consecutive years of payout increases for each. AbbVie is down 5% year to date but is supported by Skyrizi, Rinvoq, and a deep pipeline; Walmart fell after earnings but is positioned to benefit from low prices, e-commerce, and digital advertising; Becton Dickinson is improving growth prospects after spinning off a lower-growth unit and targets $1 billion in GLP-1-related revenue by decade-end. Overall tone is constructive, but this is primarily a stock-picking commentary rather than a catalyst-driven market event.

Analysis

The common thread across these names is not just “quality + dividend,” but capital-return durability in businesses with different cyclical exposures. ABBV is the cleanest long-duration cash compounding story because its growth is increasingly coming from a relatively concentrated set of high-visibility therapies; that tends to compress downside in weak macro tapes and makes any pullback more about sentiment than fundamentals. WMT is the defensive operating lever: if consumer weakness broadens, it can gain traffic share and wallet share, while its digital mix shift quietly improves margin quality even before top-line acceleration becomes obvious.

The more interesting second-order effect is on competitors and suppliers. If WMT keeps taking share, smaller grocers, dollar stores, and regional chains face margin pressure first, not revenue collapse; the real pain comes from vendor renegotiation and inventory discipline, which can ripple upstream into packaged food and discretionary suppliers. In healthcare, ABBV’s resilience matters because a successful post-patent transition narrative often expands investor willingness to pay for other large-cap biopharma with visible pipeline depth; that can create relative support across the group even if the sector is volatile.

BDX is the most overlooked because the market tends to underprice recurring consumables until volume inflects. The GLP-1 syringe angle is not just incremental revenue; it is a signal that the company can attach to the fastest-growing therapeutic category without owning the drug economics, which is a higher-probability way to participate in the obesity trade. The market may be too focused on sluggish reported growth and not enough on how divestitures and mix shift can re-rate earnings quality over the next 12–24 months.

The main contrarian risk is that investors may be reaching for perceived safety too late in the cycle. If rates stay elevated and the consumer weakens further, these “defensive” names can still de-rate despite stable cash flow because multiple compression often precedes fundamental deterioration. That argues for selective entry on weakness rather than chasing recent dips, with ABBV and WMT better suited for near-term income defense and BDX for a longer-duration turnaround-plus-growth setup.

Key Decisions for Investors

• Long ABBV on 3-6 month weakness; target a 12-18 month total return profile where dividend plus multiple re-rating can dominate if pipeline confidence holds. Risk: any setback in key growth assets or sector-wide healthcare de-rating.
• Use WMT as a recession hedge versus discretionary retail: long WMT / short a basket of higher-beta consumer names over the next 3-6 months. If traffic slows, WMT should still gain share while weaker peers absorb the margin hit.
• Initiate a patient long in BDX with a 12-24 month horizon; the setup is a laggard re-rating story, not a near-term momentum trade. Best risk/reward comes on selloffs tied to macro fear rather than company-specific deterioration.
• Consider a pair trade long WMT vs. short a regional grocer or mass merchant that lacks e-commerce/ads leverage. The thesis is margin divergence, not just revenue share gain, over the next 2 quarters.
• For income-focused portfolios, favor ABBV/WMT over lower-yield secular growers when volatility rises; the dividend floor reduces drawdown risk and can improve Sharpe if the market rotates defensive.